Valeritas Holdings, Inc. (NASDAQ:VLRX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $13.50 for the company and are forecasting that the company will post ($1.84) earnings per share for the current quarter, according to Zacks. Zacks has also given Valeritas Holdings an industry rank of 112 out of 265 based on the ratings given to its competitors.

A number of research analysts recently issued reports on the stock. ValuEngine cut shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Wedbush assumed coverage on shares of Valeritas Holdings in a report on Monday, July 10th. They set an “outperform” rating and a $12.00 price objective for the company.

WARNING: “Zacks: Brokerages Set $13.50 Price Target for Valeritas Holdings, Inc. (VLRX)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/03/zacks-brokerages-set-13-50-price-target-for-valeritas-holdings-inc-vlrx.html.

Valeritas Holdings (NASDAQ:VLRX) last issued its quarterly earnings data on Friday, August 11th. The company reported ($1.83) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.87) by $0.04. The firm had revenue of $4.79 million for the quarter, compared to analyst estimates of $5.11 million.

An institutional investor recently bought a new position in Valeritas Holdings stock. HighTower Advisors LLC purchased a new stake in Valeritas Holdings, Inc. (NASDAQ:VLRX) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 27,400 shares of the company’s stock, valued at approximately $195,000. HighTower Advisors LLC owned 1.67% of Valeritas Holdings as of its most recent SEC filing. Hedge funds and other institutional investors own 6.01% of the company’s stock.

Valeritas Holdings Company Profile

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas Holdings (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.